Status:
UNKNOWN
The Utility of PSADv (PSA Density Velocity) While on Dutasteride for Predicting Prostate Cancer Incidence and Grade and Stage
Lead Sponsor:
University Urological Associates Inc.
Conditions:
Prostate Cancer
Eligibility:
MALE
50-74 years
Brief Summary
This is a review of previously published data from a large prostate cancer prevention study known as REDUCE. It is the investigators intention to review whether prostate specific antigen (PSA) velocit...
Detailed Description
This is a review of previously published data from a large prostate cancer prevention study known as REDUCE that utilized a 5 ARI, dutasteride. It is the investigators intention to review whether PSA ...
Eligibility Criteria
Inclusion
- Men,
- 50-74 years old with elevated PSA (\>=4) along with negative entry biopsy of the prostate who had a subsequent biopsy by 24 months.
Exclusion
- Any positive biopsy of the prostate indicative of cancer upon entry
Key Trial Info
Start Date :
January 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2012
Estimated Enrollment :
6600 Patients enrolled
Trial Details
Trial ID
NCT01484808
Start Date
January 1 2012
End Date
May 1 2012
Last Update
December 2 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Division of Urology, Brown University
Providence, Rhode Island, United States, 02903